Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2017
SIETES contiene 92082 citas

 
 
 1 a 20 de 99 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]
2.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
3. Cita con resumen
Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 2017;83:642-52. [Ref.ID 101934]
5. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
6.Enlace a cita original Cita con resumen
Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, Solà I, Pequeño Saco S, Alsonso Coello P. Patients ’ and physicians ’ perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Family Practice 2017;18:1-11. [Ref.ID 101484]
7. Cita con resumen
Raccah BH, Perlman AI, Danenberg HD, Pollak A, Muszkat M, Matok I. Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure. Chest 2016;149:1516-24. [Ref.ID 101481]
9.Enlace a cita original Cita con resumen
Monaco L, Biagi C, Conti V, Melis M, Donati M, Venegoni M, Vaccheri A, Motola D. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol 2017;83:1532-43. [Ref.ID 101351]
10. Cita con resumen
Sorigue M, Sarrate E, Orna E. Hemorragia intracraneal durante el tratamiento con apixabán. Med Clin (Barc) 2017;148:47-8. [Ref.ID 101342]
11.Enlace a cita original Cita con resumen
Chin PKL, Doogue MP. Long-term prescribing of new oral anticoagulants. Australian Prescriber 2016;39:200-4. [Ref.ID 101021]
12.Tiene citas relacionadas Cita con resumen
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-1014. JAMA 2016;316:2115-25. [Ref.ID 100973]
13. Cita con resumen
Connolly SJ, Milling Jr TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albadalejo P, López-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, for the ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibotors. N Engl J Med 2016;375:1131-41. [Ref.ID 100767]
14.Enlace a cita original
Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients. Br J Clin Pharmacol 2016;82:633-44. [Ref.ID 100732]
15. Cita con resumen
Anónimo. Idarucizumab. Prescrire 2016;36:494-9. [Ref.ID 100551]
16. Cita con resumen
Anónimo. Édoxaban. Prescrire 2016;36:486-7. [Ref.ID 100546]
18.Enlace a cita original Cita con resumen
Focks JJ, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheught FWA. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016;353:i2868. [Ref.ID 100461]
19. Cita con resumen
Gómez-Outes A, Lecumberri R. Antídotos de los nuevos anticoagulantes orales: realidad y expectativas. Med Clin (Barc) 2016;146:488-90. [Ref.ID 100372]
20.Enlace a cita original Cita con resumen
Erviti López J. Incertidumbres sobre los nuevos anticoagulantes orales en fibrilación auricular Irregularidades y lagunas en su autorización. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-12. [Ref.ID 100353]
Seleccionar todas
 
 1 a 20 de 99 siguiente >>